Table 3.

Hazard ratio (95% CI) for progression-free survival among ovarian cancer patients according to ABO blood type

	ABO blood type				P value for Interaction
	Type O	Type A	Type B	Type AB
	HR (95%CI)†	HR (95%CI)†	HR (95%CI)†	HR (95%CI)†
All patients	1.00 (Ref)	0.87 (0.63-1.20)	0.83 (0.60-1.15)	0.71 (0.43-1.18)
FIGO stage					0.16
I-II	1.00 (Ref)	1.53 (0.73-3.17)	1.01 (0.46-2.24)	1.63 (0.56-4.74)
III-IV	1.00 (Ref)	0.74 (0.51-1.07)	0.78 (0.55-1.11)	0.56 (0.31-1.01)
Histological type					0.42
Serous	1.00 (Ref)	0.93 (0.65-1.35)	0.84 (0.59-1.21)	0.85 (0.49-1.48)
Non-serous	1.00 (Ref)	0.64 (0.30-1.38)	0.87 (0.42-1.80)	0.25 (0.06-1.04)
Residual disease					0.35
None detectable	1.00 (Ref)	0.91 (0.56-1.49)	0.69 (0.42-1.14)	1.08 (0.54-2.17)
≤ 1 cm	1.00 (Ref)	0.67 (0.34-1.26)	0.96 (0.51-1.81)	0.43 (0.14-1.32)
> 1 cm	1.00 (Ref)	0.85 (0.46-1.58)	0.74 (0.40-1.38)	0.47 (0.16-1.41)
Comorbidity					0.98
Yes	1.00 (Ref)	0.94 (0.60-1.46)	0.81 (0.52-1.25)	0.67 (0.35-1.29)
No	1.00 (Ref)	0.82 (0.51-1.32)	0.86 (0.53-1.38)	0.71 (0.31-1.63)

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

† HRs (95% CIs) for progression-free survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, and grading.